Description
SB-202190 (SB202190, SB 202190) is a highly selective cell-permeable inhibitor of p38 MAPK, inhibiting p38α (IC50: 50 nM) and p38β (IC50: 100 nM). SB-202190 can induce apoptosis by activating the cpp32-like caspases pathway, with typical apoptotic features such as nuclear condensation or intranuclear chromosomal DNA fragmentation.
Features
Purity≥98%
Standardized production, using factory mass production mode
Specifications
|
Cat.No. |
53005ES08/53005ES10/53005ES25 |
|
Size |
5 mg/10 mg/25 mg |
|
Synonym |
SB202190；SB 202190 |
|
Target |
p38α；p38β |
|
CAS No. |
152121-30-7 |
|
Molecular formula |
C20H14FN3O |
|
Molecular weight |
331.34 |
|
Appearance |
solid powder |
|
Purity |
≥98% |
|
Solubility |
soluble in DMSO |
|
Structure |
 |
Components
|
Components No. |
Name |
53005ES08 |
53005ES10 |
53005ES25 |
|
53005 |
SB-202190 |
5 mg |
10 mg |
25 mg |
Shipping and Storage
The SB-202190 products should be stored at -15～-25℃ for 2 years. Avoid repeated freeze-thaw cycles.
Documents:
Safety Data Sheet
Manuals
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Inquiry
You may also like
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.